Skip to main content

Trinity College Dublin, The University of Dublin

Menu Search

Trinity College Dublin By using this website you consent to the use of cookies in accordance with the Trinity cookie policy. For more information on cookies see our cookie policy.

Profile Photo

Dr. Roger Preston

Adjunct Assistant Professor (Biochemistry)


Roger Preston obtained his BSc. (Hons) in Molecular Biology from University of Aberdeen, and then completed a MSc. in Bioengineering at the University of Strathclyde. He was awarded his PhD by Imperial College London in 2004. Upon returning to Ireland, his research was funded by a Health Research Board Research Fellowship. He is currently funded by a prestigious Science Foundation Ireland Starting Investigator Research Grant. He is the recipient of research prizes from Haematology Association of Ireland (Scholar Award), Novo Nordisk ('Access-To-Insight' Research Award) and Bayer HealthCare (Hemophilia Program, Early Investigator Award).
  Blood Diseases   Hemophilia   Thrombosis
Language Skill Reading Skill Writing Skill Speaking
English Fluent Fluent Fluent
French Medium Medium Basic
Details Date From Date To
International Society of Thrombosis and Haemostasis 2007
Haematology Association of Ireland 2009 2010
Gleeson EM, O'Donnell JS, Hams E, Ni Ainle F, Kenny BA, Fallon PG, Preston RJ. , Activated Factor X signaling via protease-activated receptor 2 suppresses pro-inflammatory cytokine prodution from LPS-stimulated myeloid cells., Haematologica, 99, (1), 2014, p185 - 193, Journal Article, PUBLISHED  TARA - Full Text  DOI
Preston RJ, Rawley O, Gleeson EM, O'Donnell JS, Elucidating the role of carbohydrate determinants in regulating hemostasis: insights and opportunities., Blood, 121, (19), 2013, p3801 - 3810, Journal Article, PUBLISHED
McGrath RT, van den Biggelaar M, Byrne B, O'Sullivan JM, Rawley O, O'Kennedy R, Voorberg J, Preston RJ, O'Donnell JS. , Altered glycosylation of platelet-derived von Willebrand factor confers resistance to ADAMTS13 proteolysis. , Blood, 122, (25), 2013, p4107 - 4110, Journal Article, PUBLISHED
Gleeson EM, O'Donnell JS, Preston RJ, The endothelial cell protein C receptor: cell surface conductor of cytoprotective coagulation factor signaling., Cellular and molecular life sciences : CMLS, 69, (5), 2012, p717-26 , Journal Article, PUBLISHED
Ní Ainle F, O'Donnell JS, Johnson JA, Brown L, Gleeson EM, Smith OP, Preston RJ, Activated protein C N-linked glycans modulate cytoprotective signaling function on endothelial cells., The Journal of biological chemistry, 286, (2), 2011, p1323-30 , Journal Article, PUBLISHED  DOI
Bridges DJ, Bunn J, van Mourik JA, Grau G, Preston RJ, Molyneux M, Combes V, O'Donnell JS, de Laat B, Craig A., Rapid activation of endothelial cells enables P. falciparum adhesion to platelet decorated von Willebrand factor strings, Blood, 115, (7), 2010, p1472-1474 , Journal Article, PUBLISHED  DOI
McGrath RT, McKinnon TA, Byrne B, O' Kennedy R, Terraube V, McRae E, Preston RJ, Laffan MA, and O'Donnell JS., Expression of terminal 2-6 linked sialic acid on von Willebrand factor specifically enhances proteolysis by ADAMTS13 Blood, Blood, 115, (13), 2010, p2666-2673 , Journal Article, PUBLISHED  DOI
Preston, RJ, Tran, S, Johnson, JA, Ainle, FN, Harmon, S, White, B, Smith, OP, Jenkins, PV, Dahlbäck, B, O'Donnell, JS, Platelet factor 4 impairs the anticoagulant activity of activated protein C., The Journal of Biological Chemistry, 284, (9), 2009, p5869 - 5875, Journal Article, PUBLISHED  TARA - Full Text  DOI
Cunningham, MS, Preston, RJ, O'Donnell, JS, Does antithrombotic therapy improve survival in cancer patients?, Blood Reviews, 23, (3), 2009, p129 - 135, Journal Article, PUBLISHED  DOI
Larkin, D, de Laat, B, Jenkins, PV, Bunn, J, Craig, AG, Terraube, V, Preston, RJ, Donkor, C, Grau, GE, van Mourik, JA, O'Donnell, JS, Severe Plasmodium falciparum malaria is associated with circulating ultra-large von Willebrand multimers and ADAMTS13 inhibition., PLoS Pathogens, 5, (3), 2009, p1 - 8, Journal Article, PUBLISHED  TARA - Full Text  DOI

Page 1 of 3


Award Date
Bayer HealthCare Hemophilia Program - Early Career Investigator Award 2013
Health Research Board Research Fellowship 2006-2009
Science Foundation Ireland Starting Investigator 2009
Haematology Association of Ireland Scholar Award 2010
Novo Nordisk Access-To-Insight Award 2010
Administration of recombinant versions of endogenous plasma proteins is a common therapeutic approach to hematological and inflammatory disorders, but can be expensive, immunogenic and associated with undesirable side-effects. Dr. Preston's research seeks to address these deficiencies by generating enhanced recombinant therapeutics through innovative bioengineering of existing plasma proteins. To date, his group has developed a number of unique recombinant mutant plasma proteins possessing enhanced properties with significant therapeutic potential. These novel drug candidates have been created via manipulation of enzymatic activity, protein interaction, substrate recognition and post-translational modification. The ultimate aim of this approach is to develop new treatment approaches for adult and paediatric inflammatory, haemostatic and malignant diseases. Dr. Preston's research group is currently funded by a combination of charitable, governmental and industrial sources. These include the Paediatric Research in Translational Immunology Program at the National Children's Research Centre, a Science Foundation Ireland Starting Investigator Award and a Bayer Hemophilia Program Early Career Investigator Award.